stockaxis

Eris Lifesciences Ltd

Quarterly Result - Q2FY25

Eris Lifesciences Ltd

Pharmaceuticals & Drugs - Domestic

Current

CMP
Rs. 1306.25
Rating:
Hold
October 25, 2024

Previous

Rating:
Hold

Stock Info

BSE
540596
NSE
ERIS
Bloomberg
ERIS:IN
Reuters
ERIS.NS
Sector
Pharmaceuticals & Drugs - Domestic
Face Value (Rs)
1
Equity Capital (Rs cr)
14
Mkt Cap (Rs cr)
17734.58
52w H/L (Rs)
1522.05 - 804.00
Avg Daily Vol (BSE+NSE)
28,496

Shareholding Pattern

(as on 30-Sep)
%
Promoter
54.87
FIIs
8.01
DIIs
18.64
Public & Others
18.47
Source: Ace equity, stockaxis Research

Price performance

Return (%)
1m
3m
12m
Absolute
0.59
20.98
56.18
Sensex
-6.77
-0.80
23.97
Source: Ace equity, stockaxis Research

Indexed Stock Performance

Eris Lifesciences Ltd Sensex
Eris Lifesciences Ltd
Source: Ace equity, stockaxis Research

Financial Highlights:

Particulars (Rs. in cr) Q2FY25 Q2FY24 YoY (%) Q1FY25 QoQ (%)
Revenue from operations 741.00 505.00 47.00% 720.00 3.00%
EBITDA 265.00 181.00 46.00% 249.00 6.00%
EBITDA Margin (%) 35.76% 35.84% (8 bps) 34.58% 118 bps
PAT 96.00 122.00 -21.00% 89.00 8.00%
EPS (Rs.) 6.73 9.08 -26.00% 6.11 10.00%

Source: Company Filings; stockaxis Research

Q2FY25 Result Highlights
Eris Lifesciences reported mixed set of earnings for the quarter ended Q2FY25. The company registered robust revenue growth of 47% YoY aided by integration of Swiss Parenterals and synergies from Biocon’s portfolio. The management cited base organic business growth at 7% for H1Y25. Chronic and sub-chronic segment together accounts for 85% of the revenue. Among the businesses acquired in FY24, Biocon acquisition reported healthy run-rate of Rs.1.34bn in Q2 (flat QoQ), while Swiss Parenterals reported Rs.820mn revenue vs Rs.730mn in Q1. However, Gross Margin saw a sharp contraction by 641 bps to 74.9% due to significant changes in product/ business mix. Consolidated EBITDA witnessed a solid growth of 46% YoY to Rs.265 cr while margins stood flat at 35.7%. Base business OPM was up by 374bps YoY. PAT declined 21% YoY to Rs.96 cr. The PAT figures came in below estimates.

Key Conference call takeaways

FY25 Business Guidance

  • Total Domestic Business Formulations (DBF) revenue Rs.2,600 cr with EBIDTA margin of 36%.
  • Swiss Parenterals Revenue is projected at Rs. 330 cr with EBIDTA margin 35%.
  • Consolidated revenue is pegged at Rs.3,000 cr with EBIDTA margin of 35%.
  • Capex number is pegged at Rs. 100-120 cr for Insulins, MABs and Hormones.
  • Levim Investment Rs.54 cr.
  • Net Debt stands at Rs.2500 cr. The company is on track to reduce Debt to EBITDA from 3.5x to <2x in 18 months.
  • Capex for FY25 – Rs.220 cr while for FY26 it is projected at Rs.70-80 cr.

Other Key Highlights

  • Base business to grow at 9-10% YoY in FY25, excluding new product launches.
  • Launched ERLY, a brand of liraglutide (GLP-1); the new product pipeline to support growth in H2Y25.
  • Bhopal facility to commence production of RHI vials from next month should enhance margins starting FY26.
  • Ahmedabad facility set for ramp-up, benefiting from the 115BAB scheme, which would aid margins. 30% of the derma production undertaken in-house vs 11% in Q1.
  • Swiss Parenterals: Generated Rs.150 cr in revenue in H1Y25, guided for Rs.330 cr in H2FY25 with 35% OPM. Launched OSD-based CDMO exports with its Ahmedabad site awaiting EU-EMP inspection in Q4 and thereby will target large EU generic players.
  • Injectable: Current monthly run rate at Rs.70mn, should achieve Rs.100 cr in revenue in FY25 from the domestic market.
  • New acquisitions: Eris to invest Rs.54 cr for 30% stake in Levim; would aid end-to-end presence in biologics and provide economics of scale.
  • Insulin: Facing supply constraints, but expects 18-20% CAGR over the next 2-3 years.
  • Bhopal site to start delivering gross margin benefits in Insulin Vials starting Q4FY25/Q1FY26.

Outlook & valuation

Eris Lifesciences Ltd. delivered mixed set of numbers in Q2FY25. Eris has opted for inorganic route to diversify and scale up existing portfolio. This has been implemented without diluting margins. We expect margins to sustain at +35% as revenue scales up from recent acquisitions which is currently operating at sub optimal profitability. Acquisitions, including Swiss Parenterals and Biocon's injectable business, are expected to contribute to ERIS growth trajectory in the medium term. ERIS is also working on launching over 20 'first-to-market' products, showcasing a strong focus on innovation. The company's robust product pipeline and expected patent expirations in key therapeutic areas contribute to a positive outlook. ERIS Lifesciences Ltd exhibits strong growth potential, driven by its innovative product pipeline, strategic acquisitions, and anticipated performance in key therapeutic segments.

The company has multiple growth levers such as broad-based offerings in the derma segment, opportunities in cardio metabolic market with patent expirations, and benefits of operating leverage, as revenue scales up from these acquisitions. We expect ERIS to outperform the industry over the near to medium term, as it has established its presence in the cardiac and diabetic segments. Additionally, the new product pipeline and patent expiries provide robust growth visibility in the future. Through the organic and inorganic routes, ERIS has enhanced its offerings in dermatology, nephrology, women’s healthcare, injectables, and intensified its diabetology/cardio-vascular portfolio. At a CMP of Rs.1305, the stock is trading at 33x FY26E. We maintain HOLD rating on the stock.

Consolidated Financial statements

Profit & Loss statement

Particulars (Rs. in cr) Q2FY25 Q2FY24 YoY (%) Q1FY25 QoQ (%)
Revenue from operations 741.00 505.00 47.00% 720.00 3.00%
COGS 186.00 95.00 96.00% 181.00 3.00%
Gross Profit 555.00 410.00 35.00% 539.00 3.00%
Gross Margin (%) 74.90% 81.19% (641 bps) 74.86% 4 bps
Employee Benefit expenses 126.00 99.00 27.00% 133.00 -5.00%
Other expenses 165.00 131.00 26.00% 157.00 5.00%
EBITDA 265.00 181.00 46.00% 249.00 6.00%
EBITDA Margin (%) 35.76% 35.84% (8 bps) 34.58% 118 bps
Depreciation expenses 80.00 42.00 90.00% 76.00 5.00%
EBIT 185.00 139.00 33.00% 173.00 7.00%
Finance cost 59.00 16.00 269.00% 60.00 -2.00%
Other Income 5.00 3.00 67.00% 2.00 150.00%
PBT 129.00 126.00 2.00% 115.00 12.00%
Tax expenses 33.00 4.00 725.00% 26.00 27.00%
PAT 96.00 122.00 -21.00% 89.00 8.00%
EPS (Rs.) 6.73 9.08 -26.00% 6.11 10.00%